^
Association details:
| Biomarker: | EGFR S645C + EGFR L858R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Title:
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Published date:
10/09/2023
Excerpt:
We report a case of a 78-year-old male with lung adenocarcinoma that EGFR L858R (AF = 1.32%) coexisting with EGFR S645C (AF = 7.13%) in his diagnosed tissues analyzed by NGS. The patient was primarily resistant to first-line osimertinib…we adopted a dosage regimen of two cycles of pembrolizumab and pemetrexed from November 2021, platinum was removed because of its toxicity and side effects....CT indicated a markedly enlarged lesion (29 × 34.8 mm) in December 2021, and CEA levels remained stubbornly high (640 ng/mL).
Secondary therapy:
pemetrexed
DOI:
https://doi.org/10.2147/LCTT.S431252
